Immunomodulation in colorectal cancer: Disappointment or promise?
dc.contributor.author | Pentheroudakis, George | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Pentheroudakis, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:54:27Z | |
dc.date.available | 2018-06-22T09:54:27Z | |
dc.date.issued | 2003 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42362 | |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Levamisole | en |
dc.subject | Humans | en |
dc.subject | Cancer survival | en |
dc.subject | Chemotherapy | en |
dc.subject | Priority journal | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical trial | en |
dc.subject | Drug efficacy | en |
dc.subject | Drug safety | en |
dc.subject | Survival analysis | en |
dc.subject | Cimetidine | en |
dc.subject | Feasibility study | en |
dc.subject | Cancer radiotherapy | en |
dc.subject | Colorectal cancer | en |
dc.subject | Folinic acid | en |
dc.subject | Adjuvant | en |
dc.subject | Interferon-alpha | en |
dc.subject | Side effect | en |
dc.subject | Monoclonal antibody | en |
dc.subject | Cancer adjuvant therapy | en |
dc.subject | Colorectal neoplasms | en |
dc.subject | Randomized controlled trials | en |
dc.subject | Risk benefit analysis | en |
dc.subject | Cancer immunotherapy | en |
dc.subject | Cancer vaccine | en |
dc.subject | Drug activity | en |
dc.subject | Drug mechanism | en |
dc.subject | Drug potentiation | en |
dc.subject | Cancer regression | en |
dc.subject | Combined modality therapy | en |
dc.subject | Carcinoembryonic antigen | en |
dc.subject | Editorial | en |
dc.subject | Immunomodulation | en |
dc.subject | Cytokine | en |
dc.subject | Rna | en |
dc.subject | Immune system | en |
dc.subject | Interferon | en |
dc.subject | Cetuximab | en |
dc.subject | Postoperative care | en |
dc.subject | Cost benefit analysis | en |
dc.subject | Bcg vaccine | en |
dc.subject | Tumor antigen | en |
dc.subject | Biological response modifiers | en |
dc.subject | Corynebacterium parvum vaccine | en |
dc.subject | Edrecolomab | en |
dc.subject | Glycoprotein | en |
dc.subject | Gp 72 | en |
dc.subject | Immunotherapy | en |
dc.subject | Naked dna | en |
dc.subject | Picibanil | en |
dc.subject | Radiation injury | en |
dc.subject | Rectum surgery | en |
dc.subject | Streptococcus | en |
dc.subject | Tumor cell vaccine | en |
dc.title | Immunomodulation in colorectal cancer: Disappointment or promise? | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/annonc/mdg122 | |
dc.description.volume | 14 | |
dc.description.issue | 3 | |
dc.description.startingpage | 349 | |
dc.description.endingpage | 351 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |